Phospholipase A2: Its role in ADP- and thrombin-induced platelet activation mechanisms

International Journal of Biochemistry and Cell Biology

Volumn 30, Issue 10, 1998, Pages 1107-1122

  Puri, Rajinder N ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activation mechanism; ADP; Phospholipase A2; Platelets; Thrombin

Indexed keywords

ADENOSINE DIPHOSPHATE; PHOSPHOLIPASE A2; THROMBIN; ENZYME INHIBITOR; PHOSPHOLIPASE A;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; ENZYME ACTIVATION; HEMOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; SECOND MESSENGER; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; HELA CELL; PHYSIOLOGY;

ADENOSINE DIPHOSPHATE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; ENZYME ACTIVATION; ENZYME INHIBITORS; HELA CELLS; HEMOSTASIS; HUMANS; PHOSPHOLIPASES A; PLATELET ACTIVATION; THROMBIN;

EID: 0031596043     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(98)00080-6     Document Type: Review

References (152)

1. W. Siess, Molecular mechanisms of platelet activation, Physiol. Rev. 69 (1989) 58-178.
2. D.C.B. Mills, ADP receptors on platelets, Thromb. Haemost. 76 (1996) 835-856.
3. C. Gachet, C. Hechler, C. Léon, C. Vial, P. Ohlmann, J.-P. Cazenava, Purinergic receptors in blood platelets, Platelets 7 (1996) 261-267.
4. R.N. Puri, R.W. Colman, ADP-induced platelet activation, Crit. Rev. Biochem. Mol. Biol. 3 (1997) 432-507.
5. R.N. Puri, R.W. Colman, Purinergic receptors in human blood platelets: chemical modification and cloning investigations, J. Protein Chem. 17 (1998) 429-451.
6. J.W. Fenton II., Thrombin functions and antithrombotic intervention, Thromb. Haemost. 74 (1995) 493-498.
7. R.J.A. Grand, A.S. Turnell, P.W. Grabham, Cellular consequences of thrombin-receptor activation, Biochem. J. 313 (1996) 353-368.
8. K.P., A.S. , K.H. TurnellJakobs, Inhibition of adenylate cyclase by ADP, Thromb. Res. 18 (1980) 7-17.
9. D.E. Macfarlane, in: H. Holmsen (Ed.), Platelet responses and metabolism, CRC Press, Boca Raton, FL, 1987, pp. 19-36.
10. i-mediated inhibition of human platelet adenylate cyclase by thrombin, Eur. J. Biochem. 249 (1984) 639-643.
11. T.J. Rink, T.J. Hallam, What turns platelets on? Trends Biochem. Sci. 9 (1984) 215-219.
12. T.J. Rink, S.O. Sage, Calcium signalling in human platelets, Ann. Rev. Physiol. 52 (1990) 431-449.
13. J.S. Bennett, G. Vilaire, Exposure of fibrinogen receptors by ADP and epinephrine, J. Clin. Invest. 64 (1979) 1393-1401.
14. I.F. Charo, N. Kieffer, D.R. Phillips, Evolution, progression, and clinical manifestation of atherosclerosis: Platelet membrane glycoproteins, in: R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.), Haemostasis and Thrombosis: Basic Principles and Clinical Practice, J.B. Lippencott, Philadelphia, 1994, pp. 489-507.
15. 1 purinoreceptors in human platelets and megakaryotioblastic cell lines. Thromb. Haemost. 72 (1997) 1500-1504.
16. 1 purinoreceptor in human platelets, J. Biol. Chem. 273 (1998) 11544-11547.
17. B.B. Fredholm, M.P. Abbracchio, G. Burnstock, J.W. Daly, T.K. Harden, K.A. Jacobson, P. Leff, M. Williams, VI. Nomenclature and classification of purinoreceptors, Pharmacol. Rev. 46 (1994) 143-156.
18. S.R. Coughlin, Thrombin receptor structure and function, Thromb. Haemost. 70 (1993) 184-187.
19. J.T. Willerson, P. Golino, J. Eidt, W.B. Campbell, L.M. Buja, Specific platelet mediators and unstable coronary artry lesions: experimental evidence and potential clinical implications, Circulation 80 (1989) 198-205.
20. V. Fuster, L. Bradmon, M. Cohen, J.A. Ambrose, J.J. Bradmon, J.H. Chesboro, Insights into pathogenesis of acute ischemic syndromes, Circulation 77 (1988) 1213-1220.
21. M.J. Davis, Mechanisms of thrombosis and atherosclerosis, in: R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.), Haemostasis and Thrombosis: Basic Principles and Clinical Practice, J.B. Lippencott, Philadelphia, 1994, pp. 1224-1237.
22. J.F. Rothrock, R.G. Hart, Antithrombotic treatment of cerebrovascular disease, in: R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.), Haemostasis and Thrombosis: Basic Principles and Clinical Practice, J.B. Lippencott, Philadelphia, 1994, pp. 1224-1237.
23. R. Ross, The pathogenesis of atherosclerosis - an update, New Eng. J. Med. 314 (1986) 488-500.
24. J.H. Ip, V. Fuster, D. Israel, J.H. Chesboro, Evolution, progression, and clinical manifestation of atherosclerosis: The role of thrombotic therapy, in: R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.), Haemostasis and Thrombosis: Basic Principles and Clinical Practice, J.B. Lippencott, Philadelphia, 1994, pp. 1224-1237.
25. S. Timmons, M. Kloczewiak, J. Hawiger, ADP-depenedent common receptor mechanism for binding of von Willebrand factor and fibrinogen to human platelets, Proc. Natl. Acad Sci. USA 81 (1984) 4935-4939.
26. K. Schrör, The basic pharmacology of ticlopidine and clopidogrel, Platelets 4 (1993) 252-261.
27. S.-K. Yao, J.C. Ober, J. McNatt, C.R. Benedict, M. Rosolowski, H.V. Anderson, K. Cui, J.-P. Maffrand, W.B. Campbell, L.M. Buja, J.T. Willerson, ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries, Circulation Res. 70 (1991) 39-48.
28. E. Panak, J.P. Maffrand, C. Picard-Fraire, E. Valles, J. Blanchard, R. Rencucci, Ticlopidine: a promise for prevention and treatment of thrombus and its complications, Haemostasis 13 (Suppl. I) (1983) 1-54.
29. J. Thenault, J. McEwen, A. McCrew, C. Bouloux, C. Jacob, C. Chigot, A. Irvine, M. Kindermans, J.P. Maffrand, R. Rencucci, PCR 4099. A new antithrombotic drug, evaluation of tolerence and pharmacological activity, Thromb. Res. Suppl. 6 (1986) 286.
30. J.P. Maffrand, A. Bernat, D. Delebassee, G. Defreyn, J.P. Cazenave, J.L. Gorden, ADP plays a key role in thrombogenesis in rats, Thromb. Haemost. 59 (1988) 225-230.
31. M.J. Davis, A.C. Thomas, Plaque fissuring: the cause of acute myocardial infarction, sudden death, and crescendo angina, Br. Heart J. 53 (1985) 363-373.
32. E. Falk, Morphological features of unstable atherothrombotic plaques underlying acute coronary syndromes, Am. J. Cardiol. 63 (1989) 114E-120E.
33. R.N. Puri, R.W. Colman, Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation, Blood Coagul. Thrombol. 4 (1993) 465-478.
34. C. Tapparelli, R. Metternich, C. Ehrhardt, N.S. Cook, Synthetic and low-molecular weight thrombin inhibitors: molecular design and pharmacological profile, Trends Pharmcol. Sci. 14 (1993) 366-373.
35. L.F. Brass, Issues in the development of thrombin receptor antagonists, Thromb. Haemost. 74 (1995) 499-505.
36. S.M. Seiler, Thrombin-receptor antagonists, Semin. Thromb. Hemost. 22 (1996) 223-231.
37. E.A. Dennis, S.G. Rhee, M.M. Billah, Y.A. Hammun. Role of phospholipases in generating lipid second messengers in signal transduction. FASEB J. 5 (1991) 2068-2077.
38. S.D. Shukla, S.P. Halenda, Phospholipase D in cell signalling and its relationship to phospholipase C, Life Sci. 48 (1991) 851-866.
39. P.W. Majerus, Inositol phosphate biochemistry, Ann. Rev. Biochem. 61 (1992) 221-250.
40. M.J. Berridge. Inositol phosphate and calcium signalling. Nature 361 (1993) 315-325.
41. 2 (s); comparison of arachidonoyl-selective and -nonselective enzymes, FASEB J. 7 (1993) 339-348.
42. A.J. Morris, J. Engebrecht, M.A. Frohman, Structure and regulation of phospholipase D, Trends Pharmacol. Sci. 17 (1996) 182-185.
43. J.E. Exton, New developments in phospholipase D, J. Biol. Chem. 272 (1997) 15579-15582.
44. S.G. Rhee, Y.S. Bae, Regulation of phosphoinositide-specific phospholipase C isozymes, J. Biol. Chem. 272 (1997) 15045-15048.
45. 2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers, Trends Neu. Sci. 11 (1988) 117-123.
46. S.G. Rhee, K.D. Choi, Regulation of inositol phospho-lipid-specific phospholipase C isozymes, J. Biol. Chem. 18 (1992) 12393-12396.
47. M. Liscovitch. Crosstalk among multiple-signalling phospholipases. Trends Biol. Sci. 17 (1992) 392-399.
48. 2 enzymes: regulation and inhibition, Trends Pharmacol. Sci. 14 (1993) 92-98.
49. 2, J. Biol. Chem. 269 (1994) 13057-13060.
50. 2), FEBS Lett. 410 (1997) 49-53.
51. 2, J. Biol. Chem. 272 (1997) 16709-16712.
52. E.A. Dennis, The growing superfamily of signal transduction enzymes, Trends Biochem. Sci. 22 (1997) 1-2.
53. 2, J. Lipid Med. Cell Sign. 12 (1995) 119-130.
54. 2 gene family in mammals, J. Biol. Chem. 272 (1997) 17247-17250.
55. 2, J. Lipid. Med. Cell Sign. 12 (1995) 83-117.
56. 2, J. Lipid Med. Cell Sign. 12 (1995) 131-137.
57. 2 in canine myocardium, J. Biol. Chem. 260 (1985) 7295-7303.
58. 2 and signal transduction, Brain Res. Brain Res. Rev. 21 (1995) 152-161.
59. 2, J. Biol. Chem. 272 (1997) 16069-16072.
60. 2 - a mediator between proximal and distal effectors of inflammation, Immunology Today 12 (1991) 143-146.
61. + exchange block epinephrine-and ADP-induced stimulation of human phospholipase C by blockade of arachidonic acid release at a prior step, J. Biol. Chem. 261 (1986) 8660-8666.
62. 2 activation in human platelets, J. Biol. Chem. 261 (1986) 8667-8673.
63. 2+ mobilization in human platelets stimulated by ADP and the thromboxane mimetic U46619, J. Biol. Chem. 264 (1990) 719-725.
64. 2 in human platelets, J. Biol. Chem. 268 (1993) 26796-26804.
65. + exchange via activation of the thrombin-receptor, Biochem. J. 297 (1994) 47-52.
66. + exchange by a thrombin-receptor antagonist, Biochem. Pharmacol. 49 (1995) 519-528.
67. J.W.M. Heemskirk, S.O. Sage, Aspects of calcium signalling in platelets and other cells, Platelets 5 (1994) 295-316.
68. S.O. Sage, Calcium entry mechanisms in human platelets, Exp. Physiol. 82 (1997) 807-823.
69. T.J. Hallam, T.J. Rink, Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator Quin2, J. Physiol. 368 (1985) 131-148.
70. 2+ influx in fura-2 loaded platelets, Biochem. J. 265 (1990) 675-680.
71. M.P. Mahaut-Smith, S.O. Sage, T.J. Rink, Receptor-activated single channels in intact human platelets, J. Biol. Chem. 265 (1990) 10479-10483.
72. 1 not P2T purinoreceptors in human platelets, J. Biol. Chem. 271 (1996) 2879-2881.
73. H. Feinberg, W.C. Sandler, M. Scorer, G.C. LeBreton, B. Grossman, G.V.R. Born, Movement of sodium into human platelets induced by ADP, Biochim. Biophys. Acta 470 (1977) 317-324.
74. 2, J. Biol. Chem. 264 (1989) 5768-5775.
75. 2 which preferentially hydrolyzes an arachdonoyl residue, FEBS Lett. 282 (1991) 326-390.
76. + exchanger, Biochem. Biophys. Res. Commun. 161 (1989) 1228-1232.
77. + exchange as a modulator of platelet activation, Trends Pharmacol. Sci. 13 (1988) 148-151.
78. G.B. Zavoico, E.J. Cragoe, M.B. Feinstein, Regulation of intracellular pH in human platelets, J. Biol. Chem. 261 (1986) 13160-13167.
79. W.C. Horne, E.R. Simons, Effects of amiloride on the response of human platelets to bovine α-thrombin, Thromb. Res. 13 (1978) 599-603.
80. + eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin, Proc. Natl. Acad. Sci. USA 80 (1988) 5320-5324.
81. S.H. Ryu, U.-H. Kim, M.I. Wahl, A.B. Brown, G. Carpenter, K.-P. Huang, S.G. Rhee, Feedback regulation of phospholipase C by protein kinase C, J. Biol. Chem. 29 (1990) 17941-17945.
82. G.J. Fisher, S. Bakshian, J.J. Baldssare, Activation of human platelets with ADP causes a rapid rise in cytosolic free calcium without hydrolysis of phosphatidyl 4,5-bisphosphate, Biochem. Biophys. Res. Commun. 129 (1985) 958-964.
83. J.D. Vickers, R.L. Kinlough-Rathbone, J.F. Mustard, The decrease in phosphatidyl 4,5-bisphosphate in ADP-stimulated washed rabbit platelets is not primarily due to phospholipase C activation, Biochem. J. 237 (1986) 327-332.
84. J.D. Vickers, R.L. Kinlough-Rathbone, M.A. Packham, J.F. Mustard, Inositol phospholipid metabolism in human blood platelets stimulated by ADP, Eur. J. Biochem. 193 (1990) 521-528.
85. M.A. Packham, A.-A. Livne, D.H. Ruben, M.L. Rand, Activation of phosphalipase C and protein kinase C has little involvement in ADP-induced primary aggregation of human platelets: effects of diacylglycerols, the diacylglycerol kinase inhibitor R59022, staurosporine and okadaic acid, Biochem. J. 290 (1993) 849-856.
86. M.J. Berridge, R.F. Irvine, Inositol phosphates in cell signalling, Nature 341 (1989) 197-205.
87. Y. Nishizuka, The role of protein kinase C on cell surface signal transduction and tumor promotion, Nature 308 (1984) 693-698.
88. D.H. Haynes, Effects of nucleotides and protein kinases on platelet calcium homeostasis and mobilization, Platelets 4 (1993) 231-242.
89. 2+ homeostasis and intracellular pools in human platelets, in: K.S. Authi (Ed.), Mechanisms of Platelet activation and Control, Plenum Press, New York, 1993, pp. 83-104.
90. 1 purinoreceptor in human platelets, Blood 90 (Suppl.) (1997) 1224 abstract.
91. 1 receptor in platelets and megakaryocytic cells, Blood 90 (Suppl.) (1997) 1250 abstract.
92. P. Savi, J. Bornia, V. Salel, M. Delfaud, J.-M. Herbert, Characterization of P2X1 purinoreceptors on rat platelets: effect of clopidogrel, Br. J. Haematol. 98 (1997) 880-887.
93. C. Léon, B. Hechler, C. Vial, C. Leray, J.-P. Cazenave, C. Gachet, The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells, FEBS Lett. 403 (1997) 26-30.
94. J.B. Schacter, Q. Li, J.L. Boyer, R.A. Nicholas, T.K. Harden, Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoreceptor, Br. J. Pharmacol. 118 (1996) 167-173.
95. J. Jin, J.L. Daniel, S.P. Kunapuli, Molecular basis for ADP-induced platelet activation II: The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets, J. Biol. Chem. 273 (1998) 2030-2034.
96. + exchanger gene family: structure and function studies, Am. J. Physiol. 269 (1995) G1-G11.
97. + exchangers of mammalian cells, J. Biol. Chem. 272 (1997) 22373-22376.
98. M.P. Mahaut-Smith, S.O. Sage, T.J. Rink, Rapid ADP-evoked currents in human platelets recorded with nystatin permeabilized patch technique, J. Biol. Chem. 267 (1992) 3060-3065.
99. S.O. Sage, T.J. Rink, The kinetics of changes in intraccellular calcium concentration in fura-2-loaded human platelets, J. Biol. Chem. 262 (1987) 16364-16369.
100. S.O. Sage, T.J. Rink, Kinetic differences between thrombin-induced and ADP-induced calcium influx and release from internal stores in fura-2-loaded human platelets, Biochem. Biophys. Res. Commun. 136 (1986) 1124-1129.
101. K.M. Lerea, J.A. Glomset, E.G. Krebs, Agents that elevate cAMP in platelets decrease thrombin-binding, J. Biol. Chem. 262 (1987) 282-288.
102. M.P. Mahaut-Smith, S.O. Sage, T.J. Rink. Receptor-activated single channels in intact human platelets. J. Biol. Chem. 265 (1990) 10479-10463.
103. 2+ is necessary for thrombin-induced platelet activation, J. Biol. Chem. 264 (1989) 19600-19606.
104. 2 protein indistinguishable from lipocortin, Nature 321 (1986) 177-180.
105. M. Di Rosa, R.J. Flower, F. Hirata, L. Parente, F. Russo-Marie, Nomenclature announcement. Anti-phospholipase proteins, Prostaglandins 28 (1984) 441-442.
106. 2 by 'lipocortins' and calpactins, J. Biol. Chem. 262 (1987) 1698-1705.
107. 2 is substrate concentration dependent, FEBS Lett. 219 (1987) 176-180.
108. 2, Biochem. Pharmacol. 38 (1989) 3645-3651.
109. A. Huwiler, J. Pfeilschifter, Role of protein kinase C-α in zymosan-stimulated eicosanoid synthesis in mouse peritoneal macrophages, Eur. J. Biochem. 217 (1993) 69-75.
110. C. Godson, K.S. Bell, P.A. Insel, Inhibition of expression of protein kinase Cα by antisense cDNA inhibits phorbol ester-mediated arachidonate release, J. Biol. Chem. 268 (1993) 11946-11956.
111. 2+ and by phosphorylation by protein kinase C, J. Lipid Med. Cell Sign. 10 (1994) 23-24.
112. 2, J. Biol. Chem. 269 (1994) 19480-19487.
113. 2 is phosphorylated and activated by MAP kinase, Cell 72 (1993) 269-278.
114. W. Siess, P. Cutrecasas, E.G. Lapetina, A role for cyclooxygenase products in the formation of phosphatidic acid in the stimulated human platelets, J. Biol. Chem. 258 (1983) 4683-4686.
115. + exchange in hamster fibroblasts, EMBO J. 5 (1986) 55-60.
116. + exchanger in smooth muscle cells, J. Biol. Chem. 29 (1987) 14134-14140.
117. 2 and thrombin receptors in human platelets, Proc. Natl. Acad. Sci. USA 91 (1994) 504-508.
118. 2 in response to thrombin in rabbit platelets, Arch. Biochem. Biophys. 274 (1989) 200-208.
119. 2 activity in isolated human platelet membranes, J. Biol. Chem. 264 (1989) 21466-21469.
120. H.S. Banga, E.R. Simons, L.F. Brass, S.E. Rittenhouse, Activation of phospholipase A and C in human platelets exposed to epinephrine: Role of glycoproteins IIb/ IIIa and dual role of epinephrine, Proc. Natl. Acad. Sci. USA 83 (1986) 9197-9201.
121. 1-adrenergic stimulation in FRTL5 thyroid cells, Proc. Natl. Acad. Sci. USA 83 (1986) 7201-7205.
122. 2 by GTP-binding protein in human peripheral polymorphonuclear leukocytes, Biochem. Biophys. Res. Commun. 183 (1992) 708-713.
123. 2+ in HL-60 granulocytes, J. Biol. Chem. 267 (1992) 25966-25975.
124. 2 activity in bovine rod outer segments by the βγ subunits of transducin and its inhibition by the β subunit, Proc. Natl. Acad. Sci. USA 83 (1987) 7201-7205.
125. 2+ and mitogen-activated protein kinase regulation, J. Biol. Chem. 269 (1994) 1889-1895.
126. L.F. Brass, D.R. Manning, K. Cichowski, C.S. Abrams, Signalling through G-proteins in platelets: to the integrins and beyond, Thromb. Haemost. 78 (1997) 581-589.
127. J.S. Gutkind, The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascade, J. Biol. Chem. 273 (1998) 1839-1842.
128. 2 and arachidonic acid release in signal transduction, Biochem. Soc. Trans. 18 (1990) 503-507.
129. 2 regulated by G-proteins? Biochem. Soc. Trans. 19 (1991) 333-336.
130. A. Derksen, P. Cohen, Patterns of fatty acid release from endogenous substrates by human platelet homogenates and membranes, J. Biol. Chem. 250 (1975) 9342-9347.
131. 2 with membrane in macrophage cell line RAW 264.7, J. Biol. Chem. 265 (1990) 5409-5413.
132. H. Ariyoshi, J. Kambayashi, M. Sakon, Calpains and calpastatin in human blood platelets, Platelets 6 (1995) 185-189.
133. 2 in the pathobiology of diseases, Clin. Invest. 55 (1986) 391-404.
134. 2 inactivtion, Mol. Pharmacol. 36 (1989) 782-788.
135. 2 inhibitors, J. Cell. Biochem. 40 (1989) 279-286.
136. 2 from inflammatory exudate, Science 254 (1991) 1007-1010.
137. 2 from different sources by (R)-2-acylamino phospholipid analogues, Biochim. Biophys. Acta 1167 (1993) 281-288.
138. 2, Agents Actions 38 (1993) 202-211.
139. 2 enzymes: Selective inhibitors and their pharmacological potential, Adv. Pharmacol. 32 (1995) 31-66.
140. 2 inhibitors, Eur. J. Med. Chem. 26 (1991) 667-676.
141. 2, Agents Actions 39 (1993) C39-C42 Spec No.
142. 2+-dependent translocation domain with homology to PKC and GAP, Cell 65 (1991) 1043-1051.
143. 2, J. Biol. Chem. 266 (1991) 14850-14853.
144. 2, Biochemistry 32 (1993) 12560-12565.
145. 2 inhibitors, PCT Int. Appl. WO 8806 (1988) 885.
146. 2: Role and Function in Inflammation, vol. 275, Plenum Press, New York, 1990, pp. 169-182.
147. 2, Arch. Pharm. 329 (1996) 483-488.
148. 2, J. Med. Chem. 40 (1997) 2694-2705.
149. 2 activity is not accompanied by reduced arachidonate release, Biochem. Biophys. Res. Commun. 198 (1994) 220-227.
150. 2 in agonist stimulated platelets and Hela cells, J. Biol. Chem. 273 (1998) 4449-4458.
151. 2 is required for the formation of interferon-stimulated gene factor three, EMBO J. 15 (1996) 1566-1571.
152. 2+ transport ATPase system, Platelets 8 (1997) 5-13.